Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II

BACKGROUND AND AIMS: Ontamalimab, a fully-human monoclonal antibody targeting MAdCAM-1, induced remission in patients with moderate-to-severe ulcerative colitis [UC] in the TURANDOT study. We aimed to assess long-term safety, tolerability, and efficacy of ontamalimab in TURANDOT II. METHODS: TURANDO...

Descripción completa

Detalles Bibliográficos
Autores principales: Reinisch, Walter, Sandborn, William J, Danese, Silvio, Hébuterne, Xavier, Kłopocka, Maria, Tarabar, Dino, Vaňásek, Tomáš, Greguš, Miloš, Hellstern, Paul A, Kim, Joo Sung, Sparrow, Miles P, Gorelick, Kenneth J, Hoy, Michael, Goetsch, Martina, Bliss, Caleb, Gupta, Charu, Cataldi, Fabio, Vermeire, Séverine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218706/
https://www.ncbi.nlm.nih.gov/pubmed/33599720
http://dx.doi.org/10.1093/ecco-jcc/jjab023

Ejemplares similares

Ejemplares similares